人工智能与肝癌个体化医疗
本文综述人工智能在肝癌精准医疗中的应用,涵盖机器学习和深度学习方法在多模态数据(电子健康记录、影像、数字病理、组学)中的整合。多模态AI框架在复发和生存等关键结局上优于单模态模型,但临床转化受限于外部和前瞻性验证不足、可解释性有限及监管与工作流程整合障碍。
要点
- AI可整合临床、影像、病理和组学数据支持肝癌诊断、预后和治疗选择。
- 多模态AI模型在复发和生存预测上优于单模态模型。
- 临床转化需解决外部验证、可解释性及监管整合等障碍。
核心结论
- AI驱动的多模态决策支持系统有望改善肝癌的诊断、预后判断和治疗选择,推动个体化医疗。
研究设计与样本
- 本文为综述,围绕人工智能在肝癌精准医疗中的应用进行论述,涵盖机器学习和深度学习方法及多模态数据整合。
主要发现
- AI方法可识别大型高维数据中的复杂非线性模式,应用于电子健康记录、放射影像、数字病理和组学等多模态输入。
- 在影像中,AI支持监测、病灶检测、表征以及复发、生存和治疗反应的预测。
- 在计算病理学中,模型将组织分析从形态和标志物表达描述扩展到预后建模和肿瘤生物学推断。
- 整合临床、影像和病理数据的多模态AI框架在复发和生存等关键结局上表现优于单模态模型。
临床怎么用
- AI驱动的多模态决策支持系统若成功实施,可细化肝癌诊断、预后判断和治疗选择。
局限性
- 临床转化受限于外部和前瞻性验证不足。
- 复杂模型的可解释性有限。
- 监管和工作流程整合面临挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary liver cancers, including hepatocellular carcinoma and cholangiocarcinoma, represent a growing global health burden marked by rising incidence and high mortality. Clinical management requires integration of tumour stage, liver function, and patient-related factors to guide treatment decisions, yet current frameworks capture only a fraction of underlying disease complexity. In this setting, artificial intelligence (AI) is emerging as a key enabler of precision medicine in liver oncology. AI encompasses machine learning and deep learning approaches capable of identifying complex, non-linear patterns within large, high-dimensional datasets. These methods are increasingly applied across multimodal data inputs, including electronic health records, radiologic imaging, digital pathology, and omics profiling. In imaging, AI supports surveillance, lesion detection, characterisation, and prediction of recurrence, survival, and treatment response. In computational pathology, models are extending tissue analysis beyond description of morphology and marker expression toward prognostic modelling and inference of tumour biology. Integration of clinical, imaging, and pathological data in multimodal AI frameworks has shown superior performance compared with single-modality models for key outcomes such as recurrence and survival. Despite promising results, clinical translation remains limited by insufficient external and prospective validation, limited interpretability of complex models, and regulatory and workflow integration challenges. Addressing these barriers through federated learning strategies and the development of transparent, explainable systems is essential. If successfully implemented, AI-driven multimodal decision-support systems could substantially refine diagnosis, prognostication, and treatment selection in liver cancer, advancing personalised care in this biologically and clinically complex disease.
引用
- Matuschewski NJ, Baker W, Chapiro J, et al. Artificial intelligence and personalised medicine in liver cancer. J Hepatol. 2026. PMID: 42684194. doi:10.1016/j.jhep.2026.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。